Onkologia Medikoa
Espezialitatea
Hospital Universitari de Girona Dr. Josep Trueta
Girona, EspañaHospital Universitari de Girona Dr. Josep Trueta -ko ikertzaileekin lankidetzan egindako argitalpenak (18)
2024
2023
-
Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)
Scientific Reports
-
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513
2021
-
Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)
ESMO open, Vol. 6, Núm. 4, pp. 100215
-
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888
-
SEOM clinical guideline for management of adult medulloblastoma (2020)
Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 940-947
2020
-
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
Lung Cancer, Vol. 147, pp. 83-90
2019
-
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
Aging, Vol. 11, Núm. 9, pp. 2874-2888
-
Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer
Journal of Clinical Medicine, Vol. 8, Núm. 12
-
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125
-
The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin
Frontiers in Oncology, Vol. 9, Núm. MAR
2018
-
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study
Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704
2015
-
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
Scientific Reports, Vol. 5
2014
-
Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors
Medical Oncology, Vol. 31, Núm. 1
-
VAV3 mediates resistance to breast cancer endocrine therapy
Breast Cancer Research, Vol. 16, Núm. 3
2013
-
Basal/HER2 breast carcinomas Integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)
Cell Cycle, Vol. 12, Núm. 2, pp. 225-245
2009
-
Screening for epidermal growth factor receptor mutations in lung cancer
New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967
2003
-
Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma
Annals of Oncology, Vol. 14, Núm. 6, pp. 867-872